The promise of immuno-oncology in the neoadjuvant setting – ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“The promise of immuno-oncology in the neoadjuvant setting.

Recent studies highlight novel pre-operative therapeutic options that are showing promise.

While there are still challenges to address, early clinical trials in the neoadjuvant setting could pave the way for practice-changing strategies to help a larger number of people with cancer.

To learn more about this topic, read the ESMO Daily Reporter new column by Elena Garralda Cabanas.”

Source: ESMO/LinkedIn